Toll Free: 1-888-928-9744

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 128 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016', provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted pipeline therapeutics. 

The report provides comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) Overview 10 Therapeutics Development 11 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Stage of Development 11 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Therapy Area 12 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Indication 13 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Companies 18 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Universities/Institutes 22 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment 24 Assessment by Monotherapy/Combination Products 24 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development 30 Abeome Corporation 30 AFFiRiS AG 31 Alnylam Pharmaceuticals, Inc. 32 Amgen Inc. 33 Betagenon AB 34 BioLingus AG 35 Catabasis Pharmaceuticals, Inc. 36 Daiichi Sankyo Company, Limited 37 Eli Lilly and Company 38 HitGen LTD 39 Kowa Company, Ltd. 40 Kymab Limited 41 MedImmune, LLC 42 Merck & Co., Inc. 43 Pfizer Inc. 44 Planet Biotechnology Inc. 45 Regeneron Pharmaceuticals, Inc. 46 Serometrix, LLC 47 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 48 Thetis Pharmaceuticals LLC 49 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Drug Profiles 50 (atorvastatin calcium + TP-452) - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 alirocumab - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 ALN-PCSsc - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 ATH-04 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 ATH-06 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Biologics to Target PCSK-9 for Hypercholesterolemia - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 bococizumab - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 CAT-2000 Series - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 DS-9001 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 evolocumab - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 K-312 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 KY-1020 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 LY-3015014 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 MEDI-4166 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 O-304 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Small Molecules to Inhibit PCSK9 for Coronary Artery Disease and Metabolic Disorders - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 SX-PCK9 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 TP-452 - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Dormant Projects 106 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Discontinued Products 108 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Featured News & Press Releases 109 Jun 02, 2016: The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si 109 May 24, 2016: New Cholesterol Treatment Now Available for Canadians 109 May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting 111 May 23, 2016: The Results From A One Year Treatment Of Repatha Presented At The Annual Meeting Of The Japan Diabetes Society 112 May 16, 2016: ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards 113 May 11, 2016: Cigna's New Value-Based Contract with Sanofi/Regeneron for Praluent 114 May 11, 2016: Cigna's New Value-Based Contract with Amgen for Repatha 115 May 06, 2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke 116 May 06, 2016: NICE Sets Out Draft Recommendations For Repatha (Evolocumab) In Final Appraisal Determination 118 Apr 26, 2016: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled 119 Apr 21, 2016: Amgen Astellas Biopharma And Astellas Introduce Repatha (Evolocumab) For The Treatment Of High Cholesterol 120 Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association 121 Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association" 123 Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab 124 Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy 125 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 127 Disclaimer 128
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Comparative Analysis by Unknown Stage Development, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Development by Companies, H1 2016 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H1 2016 22 Products under Investigation by Universities/Institutes, H1 2016 23 Assessment by Monotherapy/Combination Products, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Pipeline by Abeome Corporation, H1 2016 30 Pipeline by AFFiRiS AG, H1 2016 31 Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 32 Pipeline by Amgen Inc., H1 2016 33 Pipeline by Betagenon AB, H1 2016 34 Pipeline by BioLingus AG, H1 2016 35 Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 36 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 37 Pipeline by Eli Lilly and Company, H1 2016 38 Pipeline by HitGen LTD, H1 2016 39 Pipeline by Kowa Company, Ltd., H1 2016 40 Pipeline by Kymab Limited, H1 2016 41 Pipeline by MedImmune, LLC, H1 2016 42 Pipeline by Merck & Co., Inc., H1 2016 43 Pipeline by Pfizer Inc., H1 2016 44 Pipeline by Planet Biotechnology Inc., H1 2016 45 Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 46 Pipeline by Serometrix, LLC, H1 2016 47 Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 48 Pipeline by Thetis Pharmaceuticals LLC, H1 2016 49 Dormant Projects, H1 2016 106 Dormant Projects (Contd..1), H1 2016 107 Discontinued Products, H1 2016 108


List of Figures
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Top 10 Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 24 Number of Products by Stage and Mechanism of Actions, H1 2016 25 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 28

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify